首个专门针对清除潜伏HIV-1细胞的T细胞受体（TCR）疗法已经通过了初步临床试验。这种双特异性免疫疗法可以靶向并清除那些长期携带HIV的CD4+细胞，也就是所谓的“病毒储存库”。

Notably, IFT20 clusters with TCRs at the immune synapse and associates with the ζ- and ɛ-chains of CD3 in response to TCR engagement. TCR–CD3 complex assembly is initiated in the endoplasmic ...

和T细胞受体（TCR）复合物的固定成分CD3发挥作用(CD3 X TAA) 。TCE双抗的优势在于可以通过CD3利用所有可用的T细胞，而不局限于肿瘤特异性T细胞。

Image Credit: ACROBiosystems CD3 molecules tend to bind to TCR non-covalently to develop a TCR/CD3 receptor complex on the T-cell’s surface. There are four subtypes of CD3 — CD3ε, CD3δ ...

Objectives SLE is a multifaceted autoimmune disorder with a complex pathogenesis involving genetic, environmental and ...

that consists of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes – as a treatment for unresectable or metastatic uveal melanoma.

Home > Pressemitteilung: On the way to curing type 1 diabetes ... MHH team aims to intervene in the autoimmune process and stop the destruction of insulin-producing beta cells in the pancreas ...

By bridging CD3-expressing T cells and GPRC5D-expressing tumor cells, QLS32015 facilitates T-cell-mediated destruction of cancer cells. Instead of relying on the conventional major histocompatibility ...

The therapy is a bispecific T cell engager (BiTE) molecule, consisting of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes.

“We believe that the combination of Medigene’s 3S TCR and WuXi Biologics’ CD3 mAb and bispecific platform offers the potential of a best-in-class therapeutic that precisely targets broad ...